|
|
|
|
CLINIAL DATA MANAGEMENT & ANALYTICS |
|
|
| Are We On The Cusp Of A Quantum Revolution In Clinical Trials? | Guest Column | By Scott Buchholz, Deloitte Consulting LLP | Though quantum computing is still in a nascent stage, life sciences companies are already investing in this technology to enhance predictive models, improve site selection, and find the right cohort. |
|
|
|
| Overcoming Issues Of Non-Enrolling Sites In Clinical Trials | White Paper | By Dave Hiltbrand and Dave Berry, Thermo Fisher Scientific | Explore the challenges of non-enrolling sites in clinical trials, focusing on the benefits of leveraging artificial intelligence (AI) and machine learning (ML) in addressing those issues. |
|
|
| How AI Is Changing How Clinical Research Teams Work | Article | Crucial Data Solutions | AI in clinical research serves as a "digital colleague," enhancing workflows, accelerating data analysis, and empowering study teams with precision, and insightful solutions for better patient outcomes. |
|
|
| 5 Benefits Of Using A Study Management Tool | Article | Florence Healthcare | See how study management tools simplify clinical trial management by centralizing all study information, enhancing efficiency and precision, and more. |
|
|
| How FAIR Data Principles Power Clinical Analytics Success | Webinar | Revvity Signals Software, Inc. | Explore key challenges in accessing and preparing analytics-ready clinical data, how FAIR guiding principles can help maximize the value of clinical trial data, and the impact of innovative analytics. |
|
|
| Data Analytics For Better ClinRO Quality | Article | Signant Health | Many trials fail not because of ineffective treatments, but due to challenges in detecting treatment signals. Explore how advanced data analytics can improve ClinRO quality. |
|
|
|
| Using Critical To Quality (CtQ) Factors To Identify The Critical Data For RBQM | Guest Column | By Kevin Douglass, RBQM; Jehan Poco, BDM functional excellence; and Terry Katz, Daiichi Sankyo | Based on ICH E8(R1) quality by design (QbD) principles, experts explain the use of critical to quality (CtQ) factors to identify critical data that focuses the end-to-end RBQM process on patient safety and trial results. |
|
|
| Controlled Substances In Clinical Trials | Article | By Rich Nelson, John Hufnagel, and Rachel Castro, PCI Pharma Services | Handling controlled substances presents layers of complexity. Partnering with an experienced CDMO is essential for managing scheduled materials during clinical studies. |
|
|
|
CHOOSE YOUR OWN ADVENTURE |
|
|
|
| You're receiving the Friday edition of the Clinical Leader newsletter, focusing on Clinical Data Management & Analytics and Trial Monitoring. To make changes to your newsletter selections, update your topic preferences. - Clinical Sites | Patient Centricity | Patient Recruitment (Monday)
- Clinical Trial Technology (Tuesday)
- Decentralized Trials | Trial Management (Wednesday)
- Outsourcing Models | Regulatory & Compliance (Thursday)
- Clinical Data Management & Analytics | Trial Monitoring (Friday)
Learn more about our personalized newsletters here. |
|
|
| Connect With Clinical Leader: |
|
|
|
